1 Comorbidity Profiles of Posttraumatic Stress Disorder Across the Medical Phenome.

- 2 Emily M. Hicks¹, Maria Niarchou², Slavina Goleva², Dia Kabir³, Julia Ciarcia⁴, PTSD & Trauma EHR Working
- **3** Group, Jordan W. Smoller^{3,5,6}, Lea K. Davis², Caroline M. Nievergelt^{7,8,9}, Karestan C. Koenen^{5,6,10}, Laura M.
- 4 Huckins^{*4}, Karmel W. Choi^{*3}
- 5
- 6 Affiliations:
- 7 [1] Pamela Sklar Division of Psychiatric Genetics, Icahn School of Medicine at Mount Sinai, New York, NY,
- 8 USA
- 9 [2] Vanderbilt University Medical Center, Vanderbilt Genetics Institute, Nashville, TN, USA
- 10 [3] Massachusetts General Hospital, Department of Psychiatry, Boston, MA, USA
- 11 [4] Department of Psychiatry, Division of Molecular Psychiatry, Yale University School of Medicine, New
- 12 Haven, CT, USA
- 13 [5] Broad Institute of MIT and Harvard, Stanley Center for Psychiatric Research, Cambridge, MA
- 14 [6] Massachusetts General Hospital, Psychiatric and Neurodevelopmental Genetics Unit (PNGU), Boston, MA
- 15 [7] University of California San Diego, Department of Psychiatry, La Jolla, CA
- 16 [8] Veterans Affairs San Diego Healthcare System, Center of Excellence for Stress and Mental Health, San
- 17 Diego, CA
- 18 [9] Veterans Affairs San Diego Healthcare System, Research Service, San Diego, CA
- 19 [10] Harvard T.H. Chan School of Public Health, Department of Epidemiology, Boston, MA, US
- 20
- 21

22 Abstract

Background: Prior epidemiological research has linked PTSD with specific physical health problems, but the
 comprehensive landscape of medical conditions associated with PTSD remains uncharacterized. Electronic health
 records (EHR) provide an opportunity to overcome prior clinical knowledge gaps and uncover associations with
 biological relevance that potentially vary by sex.

Methods: PTSD was defined among biobank participants (total N=123,365) in a major healthcare system using
two ICD code-based definitions: broad (1+ PTSD or acute stress codes versus 0; N_{Case}=14,899) and narrow (2+
PTSD codes versus 0; N_{Case}=3,026). Using a phenome-wide association (PheWAS) design, we tested associations
between each PTSD definition and all prevalent disease umbrella categories, i.e., phecodes. We also conducted
sex-stratified PheWAS analyses including a sex-by-diagnosis interaction term in each logistic regression.

32 **Results:** A substantial number of phecodes were significantly associated with $PTSD_{Narrow}$ (61%) and $PTSD_{Broad}$ 33 (83%). While top associations were shared between the two definitions, PTSD_{Broad} captured 334 additional 34 phecodes not significantly associated with PTSD_{Narrow} and exhibited a wider range of significantly associated 35 phecodes across various categories, including respiratory, genitourinary, and circulatory conditions. Sex 36 differences were observed, in that $PTSD_{Broad}$ was more strongly associated with osteoporosis, respiratory failure, 37 hemorrhage, and pulmonary heart disease among male patients, and with urinary tract infection, acute pharyngitis, 38 respiratory infections, and overweight among female patients. **Conclusions:** This study provides valuable 39 insights into a diverse range of comorbidities associated with PTSD, including both known and novel 40 associations, while highlighting the influence of sex differences and the impact of defining PTSD using EHR.

- 41
- 42
- 43
- 44
- 45 46
- 47
- 48

49 Introduction

50

Post-traumatic stress disorder (PTSD) occurs following highly stressful and/or traumatic events. Not only 51 52 does PTSD impair occupational performance, social relationships, and overall quality of life, it frequently 53 presents with comorbidities¹, defined broadly here as co-occurring health conditions. Common PTSD comorbidities include psychiatric conditions such as depression and anxiety^{2,3}, and physical health problems 54 including cardiovascular disease⁴ and gastrointestinal conditions⁵. However, the comprehensive landscape of 55 PTSD comorbidities, particularly in healthcare contexts, has remained incompletely characterized⁶. This limits 56 57 clinical insights into complex needs of patients with PTSD (i.e., what other medical concerns to consider in 58 formulating a treatment plan) as well as empirical insights into medical conditions that may serve as risk factors for PTSD and/or share underlying biological mechanisms⁷. 59

60 Electronic health records (EHR) provide a unique opportunity to uncover such associations with clinical 61 and potential biological relevance. EHR offer large samples and longitudinal data including all diagnoses that a 62 patient receives while active in that healthcare system, recorded using standardized diagnostic billing codes that 63 can be examined in tandem across multiple systems. Such codes can be used in different ways to identify post-64 traumatic psychopathology⁸. While PTSD is designated by specific billing codes, providers may choose to assign 65 a broader code to reflect diagnostic uncertainty, higher likelihood of insurance coverage, stigma reduction, or 66 other factors, meaning that some PTSD cases may be missed when simply focusing on a narrow set of codes. In 67 addition to identifying specific codes, we can also consider how frequently they are assigned to an individual. 68 Accordingly, a broader definition might include a single diagnosis of any stress-related disorder versus a narrow definition requiring multiple diagnoses of PTSD specifically. This has implications for epidemiologic⁹ and 69 70 genomic studies that leverage these definitions to identify PTSD cases and controls from EHR (for example, 71 GWAS^{10,11}), where a broader definition can inclusively capture more cases, enhancing discovery power, but may 72 also introduce non-specific associations¹². How we identify individuals with post-traumatic psychopathology 73 using EHR, i.e., with more inclusive versus narrow definitions, may impact our ability to resolve relevant 74 comorbidities, and the translatability of resulting genetic findings.

75 In addition to a need to resolve wide-ranging PTSD comorbidities, important sex differences may also exist in such comorbidities. The burden of PTSD varies by sex^{3,13}, with rates of lifetime PTSD about twice as high 76 77 in females compared to males¹⁴. Understanding why PTSD prevalence differs by sex is complex; rather than 78 simply capturing intrinsic biological sex differences in risk, differences may reflect gendered environments including trauma exposure (e.g., interpersonal violence)¹⁵⁻¹⁹ or available supports. Male, female, and intersex 79 80 patients may also have different experiences within healthcare systems, including where and how care is received, 81 access to care, and their diagnostic journey for PTSD. As such, the medical conditions that co-occur with PTSD 82 may also differ²⁰.

In this multi-site study, we sought to investigate the relationships between different PTSD phenotypes and the medical phenome using data from 123,365 patients enrolled in biobanks across three major EHR-based healthcare systems. Our objectives were to comprehensively identify medical comorbidities associated with PTSD, and to examine whether these associations varied based on broad versus narrow definitions, and by sex. Finally, we explored how each PTSD definition relates to polygenic signals to understand implications for downstream genomic and clinical research.

89

91 Methods

92 Samples

Our study includes 123,365 biobank research participants with available genetic and longitudinal EHR
data²¹ from three major health systems—Vanderbilt University Medical Center (VUMC, n=73,488), Mount Sinai
(MSSM, n=31,704), and Mass General Brigham (MGB, n=29,885). Sample characteristics (Table 1) and
phenotype category codes (phecodes) frequencies (Supplementary Table 1) and study information
(Supplementary Material 1) for each site are provided.

98

99 PTSD exposures

PTSD case-control phenotypes were defined using two ICD code-based definitions. Individuals who met broad PTSD criteria (PTSD_{Broad}) had \geq 1 PTSD (309.81, F43.1, F43.10, F43.11, F43.12) or stress-related disorder code (310.2, F07.81, 309, 309.1, 309.2, 309.21, 309.22, 309.23, 309.24, 309.28, 309.29, 309.3, 309.4, 309.82, 309.83, 309.89, 309.9, F43, F43.0, F43.2, F43.20, F43.21, F43.22, F43.23, F43.24, F43.25, F43.29, F43.8, F43.9), while controls had no such code; individuals who met narrow PTSD criteria (PTSD_{Narrow}) had \geq 2 PTSD codes only, while controls had no codes for PTSD, other stress-related disorders, or post-concussive injury.

106

107 Main PheWAS analyses

108 We used a phenome-wide association (PheWAS) design to test logistic regression associations between $PTSD_{Narrow}$ or $PTSD_{Broad}$ with all phecodes as previously defined²². Cases for each outcome phecode had ≥ 2 ICD 109 110 codes belonging to that phecode category, while controls had 0 codes in that category (individuals with only one 111 code were excluded). We excluded outcome phecodes derived from the same ICD codes used to define 112 PTSD_{Narrow} (phecode 300.9 ("Posttraumatic Stress Disorder")) and PTSD_{Broad} (phecodes 300.8 ("Acute Reaction to 113 Stress"), 304 ("Adjustment Reaction"), and 300.9 ("Posttraumatic Stress Disorder")) to eliminate circularity of 114 exposure and outcome. We adjusted the models for age, genetically inferred ancestry (European [EUR], African 115 [AA], Americas [AMR], East Asian [EAS], where available at each site), sex, and top 5 PCs to adjust for residual 116 differences. As a sensitivity analysis, each site also tested PheWAS models in which genetic PCs were not

117 included as a covariate. We applied a Bonferroni threshold to establish significance, correcting for 1324 tests 118 $(pBONF<3.7x10^{-5}; PTSD_{Narrow})$ and 1367 tests $(pBONF<3.8x10^{-5}; PTSD_{Broad})$. We assessed enrichment of phecode 119 categories of associations reaching Bonferroni significance, and the top 25% of associations, using a binomial 120 test.

For all phecodes appearing in ≥ 2 sites in the analysis (1649 phecodes were available for ≥ 2 sites; 765 were available for all three sites), we meta-analyzed across sites using fixed-effects in the *PheWAS* R package²³. To assess heterogeneity, we calculated I² statistics in METAL²⁴ to identify associations that differed in effect sizes between health systems. Phecodes with I²<0.1 were considered significantly heterogeneous. While we observed significant heterogeneity among effect size estimates across sites for both PTSD_{Narrow} and PTSD_{Broad} PheWAS, directions of effect and top associations across sites remained largely uniform (**Supplementary Table 2**).

127

128 Sex-stratified and sex-interaction PheWAS Analyses

We conducted sex-stratified PheWAS analyses (n=13,228 female, n=11,614 male), adjusting for age, ancestry, and top 5 PCs. Patient sex was categorized as follows: MGB: sex assigned at birth, VUMC: sex assigned at birth, Mount Sinai: karyotypic sex; a small number of intersex individuals and individuals who declined to state their sex were excluded from this analysis. For all Bonferroni-significant phecodes from the full or sex-stratified analyses, we conducted an analysis including a sex-by-diagnosis interaction term in each logistic regression. Interaction effect sizes were meta-analyzed using an inverse-variance weighted model using a "STDERR" scheme with METAL software²⁴.

136

137 Polygenic score analyses

We assessed genetic correlates of PTSD definitions in individuals of European (EUR) and African ancestries (AA) based on PTSD polygenic scores (PGS). We calculated PGS inferring SNPs weights from European PGC-PTSD GWAS summary statistics (discovery n=174,659)²⁵ as implemented in PRS-CSx²⁶ and summing allele counts weights. For each available ancestry group within each health system, we normalized the PGS and tested their association with PTSD_{Narrow} or PTSD_{Broad} using logistic regression, including sex, age, and

- 143 within-ancestry genotype-derived principal components (PCs). We estimated phenotypic variance explained by
- 144 PTSD scores using Nagelkerke's R^{2} ²⁷. We meta-analyzed PGS associations with fixed effects using the metafor
- 145 $package^{28}$.

146 **Results**

147 Sample

To examine phenome-wide comorbidities of PTSD, we conducted analyses included 123,365 patients (3,026 and 14,899 meeting the $PTSD_{Narrow}$ versus $PTSD_{Broad}$ definitions, respectively) across three major healthcare systems: VUMC, MGB and MSSM (**Table 1**). Prevalence of $PTSD_{Narrow}$ and $PTSD_{Broad}$ at MGB (4.32% and 22.14%, respectively) were higher than the other two sites (VUMC: 1.9% and 9.37%, MSSM: 1.69% and 6.98%).

153

154 Narrowly and broadly defined PTSD definitions have wide-ranging correlates across the medical phenome

155 807 of 1324 (61%) phecodes were significantly associated with PTSD_{Narrow} and 1136 or 1367 (83%) with 156 $PTSD_{Broad}$ (p_{Bont}<3.8x10⁻⁵, 3.7x10⁻⁵, respectively; full summary statistics: Supplementary Table 2). Top PTSD_{Narrow} associations included psychiatric and pain-related phecodes, whereas top PTSD_{Broad} associations 157 158 included psychiatric and pain-related phecodes as well as respiratory, genitourinary, and circulatory phecodes 159 (Figure 1). Phecode associations with PTSD were primarily positive: we observed an increased risk of each of 160 these phecodes among individuals with PTSD. Only a very small minority of phecodes was negatively associated 161 with PTSD, including regional enteritis (Crohn's) (p=0.019, OR=0.77; p=0.0061, OR=0.86 for PTSD_{Narrow} and PTSD_{Broad}, respectively) and prostate cancer (p=0.014, OR=0.61; p=0.022, OR=0.87) (Supplementary Table 2). 162 163 Notably, these negative directions of effect were consistent across all sites.

164

165 Narrowly-defined PTSD shows strong associations with neuropsychiatric traits

PTSD_{Narrow} was associated with over 85% of phecodes in the mental disorders category (**Supplementary Table 3**). Among the top 25% of phecodes associated with PTSD_{Narrow}, 'mental disorders' and 'symptoms' categories were significantly enriched after Bonferroni correction (**Supplementary Table 3**). The strongest associations with PTSD_{Narrow} fell in the mental disorders category, including personality disorders (*Antisocial/borderline personality disorder, Personality disorders*); mood disorders (*Mood disorders, Depression*); suicide-related phecodes (*Suicidal ideation, Suicidal ideation or attempt*); substance use disorders

(Substance addiction and disorders, Alcohol-related disorders); and anxiety disorders (Agorophobia, social
phobia, and panic disorder, Anxiety disorder, Generalized anxiety disorder). Beyond the mental disorders
category, PTSD_{Narrow} was associated with over 85% of phecodes in the infectious diseases category
(Supplementary Table 3). Phecodes with the largest odds ratios in association with PTSD_{Narrow} were Anxiety
Disorders, Antisocial/borderline personality disorder, personality disorder, mood disorder, suicidal ideation,
suicide or self-inflicted injury, poisoning by psychotropic agents, and depression.

Additionally, PTSD_{Narrow} showed strong associations with phecodes in the neurological and symptoms categories pertaining to pain, including *Chronic pain, Back pain, Pain*, and *Nonspecific chest pain*. Several genitourinary phecodes also emerged in association with PTSD_{Narrow}, for example, *Other symptoms/disorders of the urinary system*, *Urinary tract infection*, and *Dysuria*.

182

Broadly-defined PTSD shows strong associations with neuropsychiatric traits and respiratory, digestive, genitourinary, and cardiovascular conditions

185 PTSD_{Broad} was significantly associated with all phecodes in the mental disorders and infectious disease 186 categories and over 90% of phecodes in the respiratory, injuries & poisonings, symptoms and digestive categories 187 (Supplementary Table 3). Among the top 25% of significant phecodes, mental disorders, symptoms, and 188 respiratory PheCode categories were significantly enriched (Supplementary Table 3). The top phecode 189 associations with PTSD_{Broad} included mood disorders (depression, suicidal ideation, anxiety, bipolar disorder), 190 substance use disorders (Substance addiction and disorders, alcohol related disorders alcoholism, tobacco use 191 disorder), and other psychiatric disorders (schizophrenia, ADHD). The phecodes with the largest odds ratios in 192 association with PTSD_{Broad} were antisocial/borderline personality (OR=18.8 (18.61-19.00)), personality disorder 193 (OR=13.21 (13.07-13.34)), suicidal ideation (OR=9.4 (9.30-9.51)), and anxiety disorders (OR=9.37 (9.33-9.41)).

In addition to mental disorders, top associations with PTSD_{Broad} were related to a wide range of medical phecode categories, including sleep (*insomnia, sleep disorders, malaise and fatigue*), pain (*back pain, chronic pain, abdominal pain, pain, pain in joint*), respiratory system (*other symptoms of respiratory system, cough, acute upper respiratory infections of multiple or unspecified sites, shortness of breath, pneumonia*), digestive system

(nausea and vomiting, GERD, diseases of esophagus, esophagitis), genitourinary system (urinary tract infection,
other symptoms disorders of the urinary system, dysuria), cardiovascular system (nonspecific chest pain, cardiac

201

202 Clinical phenome associations were largely shared but showed some differences across PTSD definitions

Significant phecode associations were largely shared between PTSD_{Narrow} and PTSD_{Broad} definitions, 203 204 especially the top-ranking associations (Figure 2). However, many more phecodes were significantly associated 205 with PTSD_{Broad} (1136/1367 tested) compared to PTSD_{Narow} (807/1324), and 334 Bonferroni-significant phecodes 206 were associated with PTSD_{Broad} but not PTSD_{Narrow}. The strongest such associations included phecodes related to 207 skin (neoplasms of skin, dyschromia, actinic keratosis, other non-epithelial cancer of skin, dermatitis), lung 208 transplant and chronic pulmonary heart disease; however, these phecodes were not among the strongest hits for 209 PTSD_{Broad}. Only four phecodes were significantly associated following Bonferroni correction with PTSD_{Narrow} but 210 not $PTSD_{Broad}$. These included relatively uncommon genitourinary phecodes such as urethral hypermobility/ISD, 211 pelvic peritoneal adhesions, as well as amblyopia, and other disorders of middle ear and mastoid.

212

213 Sex moderates associations between broadly-defined PTSD and several other phenotypes

214 We conducted sex-stratified PTSD_{Narrow} and PTSD_{Broad} PheWAS, and meta-analyzed across sites 215 (Supplementary figures 1-2; Supplementary Table 4), and performed a PTSD-by-sex interaction test restricted to 216 only those phecodes with a Bonferroni-significant main effect within either sex (Figure 3). There were 16 phecodes 217 that were significantly different between males and females coded with PTSD_{Broad} after meta-analysis. Phenotypes 218 that were more common among male patients with $PTSD_{Broad}$ included osteoporosis, respiratory failure, 219 subarachnoid and intracranial hemorrhage, and pulmonary heart disease. Phenotypes that were more common 220 among female patients with PTSD_{Broad} included urinary tract infection and other urinary symptoms, acute 221 pharyngitis, acute respiratory infections, and overweight, though directions of effect were not consistent between 222 sites for some phecodes. For PTSD_{Narrow}, other symptoms/disorder of the urinary system was the only phecode

²⁰⁰ *dysrhythmias, hypertension, hypotension, arrhythmia, palpitations*), and asthma conditions.

with a significant sex interaction, driven by higher prevalence in males at MGB despite opposing associationsobserved at the other two sites.

225

226 Explanatory power of polygenic scores varies according to PTSD definition.

We tested PGS associations with both $PTSD_{Narrow}$ and $PTSD_{Broad}$ (**Table 2**). PTSD PGS significantly associated with both $PTSD_{Narrow}$ (meta-analytic B=0.17, SE=0.02, p=5.6E-14, R² range= 0.08-0.29%; total cases: 11,075) and $PTSD_{Broad}$ (meta-analytic B=0.07, SE=0.01, p=2.7E-11, R² range=0.08-0.43%; total cases: 2,116) in EUR subsamples, although the proportion of variance explained (R²) was low. PGS were not significantly associated among AA individuals for either $PTSD_{Narrow}$ (B=0.06, SE=0.09, p= 0.30, R² range=0.0002-0.04%) or PTSD_{Broad}(B=0.01, SE=0.09, p=0.53, R² range=0.006-0.32%), likely due to poor representation of African ancestry alleles in existing PTSD GWAS.

235 Discussion

236 This study examined phenome-wide relationships between EHR-based PTSD and over 1300 medical 237 phecodes among over 123,000 participants across 3 health systems, including 14,899 and 3,026 individuals 238 meeting broad and narrow definitions for PTSD, respectively. We identified known and novel PTSD 239 comorbidities that replicated across multiple health systems and contextualized the relative strength of PTSD-240 related associations across the medical phenome. Additionally, we identified several phenotypes for which males 241 and females exhibit differing relationships with PTSD. These results characterize a wide range of PTSD-related 242 diagnostic comorbidities in a health system setting and provide a useful catalog of phenotype-phenotype 243 relationships for interpreting future biobank-based genetic association studies of PTSD.

244

245 Contextualizing known and novel PTSD comorbidities

Our results build upon known psychiatric²⁹⁻³¹ and non-psychiatric PTSD comorbidities. Psychiatric 246 247 disorders were consistently identified as the strongest comorbidities for both broad and narrow PTSD definitions; 248 among non-psychiatric disorders, we observed a strong association of both PTSD definitions with pain 249 phenotypes, which encompass physical sensory components, as well as cognitive and emotional components³²⁻³⁶. Given inflammatory/immune links to PTSD³⁷, we were surprised to find that autoimmune disorders such as 250 251 rheumatoid arthritis and multiple sclerosis were not significantly associated with PTSD. This suggests these 252 comorbidities may be less common on a health system scale, or that these comorbidities present with specific 253 PTSD subtypes (for example, those with a specific immune component or etiopathology) that are not well 254 represented or captured in our biobanks. Unexpectedly, we did not find significant associations between PTSD and decreased libido³⁸. However, this phecode is relatively scarce in our biobanks (N=162-214), decreasing our 255 256 ability to detect associations. We identified novel associations of genitourinary phenotypes with PTSD, with a 257 particularly strong association with PTSD_{Broad}, with significance levels comparable to respiratory and 258 cardiovascular comorbidities. It is possible that these associations stem from shared risk factors, i.e., that sexual 259 assault or related traumatic experiences lead to both genitourinary and psychiatric outcomes³⁹, or are artefactual 260 associations resulting from cross-disorder correlations, where conditions that appear significant are not directly

associated with the exposure but rather linked to other diseases. It is also possible these associations reflect 'healthcare pleiotropy'' – i.e., the association stems from an artifact of the clinical settings where traumatic exposures are more commonly/routinely discussed (i.e., OB/GYN clinics).

264

265 Sex differences in PTSD comorbidities

266 Epidemiological evidence indicates that females exposed to traumatic events are at higher risk for 267 developing PTSD compared to trauma-exposed males. We identified several phenotypes for which associations 268 with PTSD_{Broad} differed between males and females. For females, obesity had a stronger association with PTSD than males. This relationship has been previously reported for some studies of PTSD^{40,41} and other psychiatric 269 phenotypes⁴². We also found stronger association of urinary symptoms with PTSD in females. This may be due to 270 271 genito-urinary symptoms that occur at higher rates following exposure to abuse³⁸; for example, interstitial cystitis/bladder pain syndrome⁴³, vulvodynia⁴⁴, and chronic pelvic pain^{45,46}, coupled with a greater prevalence of 272 sexual trauma among females^{17,47} or perhaps due to the clinical setting where trauma and genitourinary symptoms 273 274 are assessed. Respiratory failure, cranial hemorrhage, and pulmonary heart disease were more prevalent among 275 male PTSD_{Broad} cases. Together these results may reflect differential patterns of diagnosis of these disorders or 276 PTSD, differences in the care received between sexes (for example, in medical fields with sex specificity like 277 gynecology) or sex differences in PTSD pathology and the downstream system-wide consequences of having 278 PTSD.

279

280 Scope of PTSD phenotyping and implications for genetic studies

This study explored the role of phenotypic specificity in resolving comorbid phenotypes. A narrow definition requiring multiple PTSD codes likely captures individuals with more severe and specific symptomatology. In contrast, the broad definition, consisting of a single code inclusive of stress-related reactions, may include individuals with a broader range of symptom severity. Psychiatric genetic studies increasingly tend to include broader definitions which facilitate greater sample sizes, but at the potential cost of specificity¹². Both PTSD definitions showed strikingly high levels of comorbidities. However, we found top PTSD_{Narrow} associations

were concentrated in mental disorders and pain-related symptoms, whereas PTSD_{Broad} associations were spread across more phecode categories such as respiratory, genitourinary and circulatory conditions. Generally, the top phecodes were consistent across both definitions, with the broader definition associated with 300 additional phenotypes.

291 These association patterns have significant implications for our understanding of broad vs. narrow 292 definitions of psychiatric disorders and may shape future analytical and inclusion/exclusion criteria, as well as 293 how we should interpret associations specific to PTSD_{Broad}. The most significant of these were skin conditions 294 (dyschromia, actinic keratosis etc.), which may reflect racial differences in PTSD prevalence, trauma exposure, or diagnostic rates¹⁵. To assess relevance for future studies, we consider each definition. If PTSD_{Broad} captures both 295 296 full PTSD and sub-threshold PTSD cases (or, if an accurate diagnosis is obtained using only one ICD code, 297 PTSD_{Broad} may capture primarily full PTSD cases), then we might conceptualize these associations as true PTSD 298 associations, discoverable only thanks to this increase in power. However, if the broad category involves 299 decreased diagnostic accuracy, $PTSD_{Broad}$ may simply add 'noise' to the analysis, rather than identifying sub-300 threshold or otherwise 'missed' cases, and these additional associations may not contribute meaningfully to our 301 understanding of PTSD and its comorbidities. At the genetic level, we observed that a PTSD PGS (trained on a GWAS based on mainly studies of clinically ascertained PTSD²⁵) significantly associated with both PTSD_{Broad} 302 303 and PTSD_{Narrow} status, though more strongly PTSD_{Narrow} than PTSD_{Broad}. In the future, as sample sizes for PTSD 304 GWAS increase, focusing on more strictly defined cases may become more feasible and may lead to increased 305 predictive power of PGS.

Several factors suggest that the former, rather than latter, conceptualization is correct. First, addition of truly random cases (i.e., introduction of 'noise') should reduce PheWAS discovery power⁴⁸ rather than identify additional significant associations. Second, both $PTSD_{Broad}$ and $PTSD_{Narrow}$ have significant psychiatric associations; it does not appear that one group is obviously more 'accurately' ascertained that the other. Third, we note a primary difference between the two groups reflects frequency of diagnosis; a single ICD code for PTSD does not necessarily imply an incorrect diagnosis, sub-clinical presentation, or less severe symptoms (this could be examined through in-depth chart reviews in the future); rather, these patients may leave the medical system or be

referred elsewhere for treatment. In particular, we note that MSSM is associated with a VA, where veterans
experiencing combat-related PTSD may pursue PTSD care instead of the initial diagnostic site.

315

316

317 Strengths and limitations

318 Our study has several limitations to note when assessing and interpreting our results. First, while studying 319 the full clinical phenome using EHR is a strength of our study, our biobank-based patient populations may not be 320 fully representative of the general population. To some extent, we mitigate this concern by comparing effect sizes and meta-analyzing⁴⁸ across three healthcare settings that represent distinct geographical areas (Boston, New 321 322 York, Nashville), with differing demographics and healthcare needs (e.g., the proportion of veterans seeking care 323 at these clinics differs significantly), and differing proportions of individuals with PTSD. In particular, one site 324 (MGB) has a much higher rate of PTSD diagnosis (PTSD_{Narrow}: 4.3% vs 1.9%, 1.7% at VUMC, MSSM, 325 respectively). Consequently, we observe some heterogeneity in effect size of associations; however, effect 326 directions are largely consistent across all three sites, which is highly unlikely to be due to chance (655 327 concordant across three sites vs. 169 discordant: binomial $p=4.84 \times 10^{-236}$; for codes present in two sites only: 340 328 concordant vs. 126 discordant, binomial $p=9.06 \times 10^{-24}$).

Given the majority of individuals are seeking care in a hospital setting for some symptom or condition, 329 330 EHR-based analyses likely underestimate the proportion of healthy individuals and will not identify sub-threshold 331 PTSD or those with well-managed PTSD receiving care in a different system. Our analysis also does not adjust 332 for utilization rates. Relatedly, individuals in our study may have uneven access to healthcare or to certain 333 specialists within a healthcare system: psychiatric or mental health services in particular may be unevenly 334 accessed due to differences in insurance coverage or stigma or immigration status. Even when healthcare is 335 accessed, patients may receive differing levels of care and stereotyping bias or institutionalized racism in 336 healthcare may lead to under- or over-diagnosis⁴⁸⁻⁵⁰. These issues may be particularly exacerbated in psychiatry, 337 where certain presentations of PTSD may be more readily diagnosed, potentially biasing our comorbidity results 338 towards that subtype of PTSD.

339 Another limitation is the lack of temporal resolution. Understanding whether these associated phecodes 340 occur prior to, or following, PTSD onset would ideally allow us to delineate associations into antecedents versus 341 potential consequences of PTSD diagnosis. However, this is difficult in practice: patients may report longstanding 342 existing diagnoses to a clinician upon enrollment at a new clinic, or receive correct diagnoses after long diagnostic 343 journeys. In the latter case, a patient may experience initial symptoms several years before an accurate diagnosis 344 of PTSD, such that other diagnoses received may either be comorbid with PTSD or represent inaccurate diagnoses 345 given to explain some of the PTSD symptoms (for example, MDD, or adjustment reaction disorder). Difficulty in 346 pinpointing disease onset precludes analysis of temporal relationships. Informed by this comprehensive map of 347 associations, studies should be repeated in longitudinal cohorts with detailed and repeated psychiatric 348 questionnaires that provide nuanced temporal resolution and can help shed light on the temporal nature of these 349 phenotype-phenotype relationships in PTSD. Further exploration of the genetic factors contributing to PTSD and 350 its comorbidities is also warranted.

351

352 Conclusions and future directions

353 This multi-site study investigated relationships between PTSD phenotypes and medical comorbidities 354 using data from over 123,000 patients across three major EHR-based healthcare systems. Our findings provide 355 insights into the diagnostic complexity of PTSD and its associations with the clinical phenome. By considering 356 both broad and narrow PTSD definitions, we comprehensively identified known and novel diagnostic 357 comorbidities, particularly in the domains of mental disorders, pain, respiratory, genitourinary, and cardiovascular 358 conditions. These associations were observed across multiple health systems, highlighting their generalizability. 359 Importantly, we observed sex differences in the associations between PTSD and certain medical phenotypes, 360 underscoring the need to consider sex-specific factors. Furthermore, our genetic analyses revealed significant 361 associations between polygenic scores derived from GWAS and both broad and narrow definitions of PTSD. 362 Future research should include longitudinal analyses to examine temporal relationships between PTSD and 363 medical comorbidities, providing insights into the directionality of these associations. Investigating sex-specific 364 factors, such as hormonal influences, trauma response differences, or care-seeking patterns, will enhance our

365 understanding of sex disparities in PTSD and associated medical conditions, while mechanistic studies could 366 explore underlying biological pathways and shared genetic factors contributing to the observed associations. 367 Overall, this study deepens our understanding of the diagnostic complexity of PTSD within EHRs and provides 368 insights for research towards integrated treatment approaches that address both PTSD diagnosis and its 369 comorbidities.

371 Acknowledgements:

372

This collaborative work was supported in part by the PsycheMERGE grant MH118233 (to JWS and LKD) and
administrative supplement to PGC PTSD R01 (R01MH106595). KWC was supported in part by funding from the
National Institute of Mental Health (K08MH127413) and a NARSAD Brain and Behavior Foundation Young
Investigator Award. EMH, JC and LMH acknowledge funding from NIMH (R01MH124839, R01MH118278)
and NIEHS (R01ES033630). LKD was supported by NIMH (R01MH118223); NHGRI and the Office of Research
on Women's Health (RM1HG009034).

MSSM: This work was supported in part through the computational resources and staff expertise provided by Scientific Computing at the Icahn School of Medicine at Mount Sinai under award number S10OD018522 from the Office of Research Infrastructure of the National Institutes of Health. This work was supported through the resources and staff expertise provided by the Charles Bronfman Institute for Personalized Medicine and the Bio*Me* Biobank Program at the Icahn School of Medicine at Mount Sinai.

384 BioVU: The dataset(s) used for the analyses described were obtained from Vanderbilt University Medical Center's

385 BioVU which is supported by numerous sources: institutional funding, private agencies, and federal grants. These

include the NIH funded Shared Instrumentation Grant S10RR025141; and CTSA grants UL1TR002243,

387 UL1TR000445, and UL1RR024975. Genomic data are also supported by investigator-led projects that include

388 U01HG004798, R01NS032830, RC2GM092618, P50GM115305, U01HG006378, U19HL065962, R01HD074711;

389 and additional funding sources listed at <u>https://victr.vumc.org/biovu-funding/</u>. This publication was supported by Grant

390 No. R01 HG011405, partially funded by the Office of Research on Women's Health, Office of the Director, NIH and the

391 National Human Genome Research Institute. Its contents are solely the responsibility of the authors and do not necessarily

392 represent the official views of the Office of Research on Women's Health or the National Human Genome Research Institute.

393

394 Disclosures: JWS is a member of the Scientific Advisory Board of Sensorium Therapeutics (with equity), and has 395 received grant support from Biogen, Inc. He is PI of a collaborative study of the genetics of depression and 396 bipolar disorder sponsored by 23andMe for which 23andMe provides analysis time as in-kind support but no 397 payments.

398



399

Figure 1. A) PheWAS meta-analysis results for the narrow PTSD definition. B) PheWAS meta-analysis results for the broad PTSD definition. Phecodes are organized across the y-axis by their category, with the strength of association shown in the x-axis using -log10p. Red dashed line indicates the Bonferroni significance threshold. Bonferroni (**) and nominally significant (*) phecode category enrichments for the top 25% of phecode associations for PTSD_{Narrow} (mental disorders: p<0.0001, symptoms: p=0.0001, neurological: p=0.0019, respiratory=0.0081) and PTSD_{Broad} (mental disorders: p<0.0001, symptoms: p<0.0001, respiratory: p=0.0007, neurological: p=0.0269, musculoskeletal: p=0.0324, endocrine/metabolic: p=0.0312)

407



410 **Figure 2.** Top PheWAS hits are shared between narrowly and broadly defined PTSD. Phecodes ranked by p value 411 are plotted for $PTSD_{Broad}$ (x-axis) and $PTSD_{Narrow}(y-axis)$. Phecodes with Bonferroni significant association with 412 $PTSD_{Narrow}$ (blue), $PTSD_{Broad}$ (red), both (purple) or neither (gray) are indicated. Number of shared and distinct 413 phecode associations for $PTSD_{Narrow}$ and $PTSD_{Broad}$ are shown in the inset.

414



416 Figure 3 Phecodes with significant sex interaction with $PTSD_{Narrow}$ (A) and $PTSD_{Broad}$ (B) in at least one site or in 417 meta-analysis across sites. Interaction term (PTSD * Sex) coefficients and standard errors are plotted for each site 418 independently (MGB=blue, VUMC=green, MSSM=purple) and for a meta-analyzed interaction term coefficient 419 (red). Bonferonni significant interaction terms are indicated with a filled circle. Positive interaction term indicates 420 a higher prevalence in males and a negative interaction term indicates a higher prevalence in females.

- 421
- 422 Tables

Table 1: Sample Character	istics by Site					
			VUMC	MGB	MSSM	
	N		73488	29885	19992	
Full Sample	Current age (mean (SD; range))		59.66(19.53; 18-100)	61.55 (16.73; 22-105)	56.82 (16.51; 19-107)	
	Sex (N, % of females)		42106(57.3)	16413 (54.9%)	11970 (59.87%)	
		% European	62204(84.6%)	25787 (86.3%)	6554 (32.78%)	
	Ancestry	%African American	11284(15.4%)	1562 (5.2%)	5222 (26.12%)	
		% Hispanic	N/A	N/A	7130 (35.66%)	
		% Admixed Americans	N/A	N/A 1797 (6.0%)		
		% East Asian	N/A	455 (1.5%)	596 (2.98%)	
		% Native American	N/A	N/A	57 (0.29%)	
		% South Asian	N/A	284 (1.0%)	407 (2.04%)	
	Number of ICD codes (mean, (SD; range))		258.3(375.2; 1-6937)	416 (540; 1-15722)	35.2(31.592; 1-232)	
	PTSD Narrow N		1399	1290	337	
PTSD Narrow cases	Current age (mean (SD; range))		47.67(16.65; 18.1-95.3)	52.07 (15.06; 23-94)	54.95 (11.54; 22-87)	
	Sex (N, % of females)		987 (70.6%)	914 (70.9%)	223(66.17%)	
		% European	1131(80.8%)	974 (75.5%)	51(15.13%)	
	Ancestry	%African American	268(19.2%)	116 (9.0%)	97(28.78%)	
		% Hispanic	N/A	N/A	185(54.9%)	
		% Admixed Americans	N/A 189 (14.7%)		1(0.3%)	
		% East Asian	N/A	7 (0.5%)	1(0.3%)	
		% Native American	N/A	N/A	2(0.59%)	
		% South Asian	N/A	4 (0.3%)	N/A	
	Number of ICD codes (mean, (SD; range))		524.9(648.8; 9-6937)	855 (859; 10-11073)	69.6 (36.51; 6-179)	
	PTSD Broad N		6887	6616	1396	
PTSD Broad cases	Current age (mean (SD; range))		55.14(18.5; 18.02-99.5)	59.90 (16.40; 23-101)	56.59 (15.66; 21-101)	
	Sex (N, % of females)		4557(66.2%)	4176 (63.1%)	1005(71.99%)	
		% European	5796(84.2%)	5285 (79.9%)	235(16.83%)	
		%African American	1091(15.8%)	558 (8.4%)	461(33.02%)	
	Ancestry	% Hispanic	N/A	N/A	665(47.64%)	
		% Admixed Americans	N/A	670 (10.1%)	3(0.21%)	
		% East Asian	N/A	65 (1.0%)	17(1.22%)	
		% Native American	N/A N/A		5(0.36%)	
		% South Asian	N/A	38 (0.6%)	10(0.72%)	
	Number of ICD codes (mean, (SD; range))		538.2(621.1; 4-6933)	753 (751; 5-11073)	67.78 (37.43; 1-216)	

Table 1. Sample characteristics by site.

Table 2: PGS Meta-analysis association statistics									
			PTSD ~ PRS	S + Age + Sex	+ PCs1:5	where PRS	is scaled		
Ancestry Group	PTSD Definition	Site	Beta	se	р	N case	N control	N total	Nagelkerke 1
EUR	Narrow	MGB	0.1951	0.0344	0.0000008	936	19591	20527	0.425%
		VUMC	0.1500	0.0300	0.00000179	1131	56168	57299	0.230%
		BioMe	0.1117	0.1719	0.51576118	49	6307	6356	0.078%
		META-ANALYSIS	0.1685	0.0224	5.6E-14				
	Broad	MGB	0.0653	0.0161	0.0000476	5059	19765	25698	0.081%
		VUMC	0.0700	0.0140	0.0000018	5796	56408	62204	0.083%
		BioMe	0.1800	0.0824	0.0290112	220	6137	6357	0.291%
		META-ANALYSIS	0.0698	0.0105	2.7E-11				
AA	Narrow	MGB	-	-	-	-	-	-	-
		VUMC	0.0250	0.0700	0.7226	268	10158	10426	0.006%
		BioMe	-0.1723	0.1041	0.0980	96	5062	5158	0.315%
		META-ANALYSIS	-0.0364	0.0581	0.5305				
	Broad	MGB	-	-	-	-	-	-	-
		VUMC	0.0500	0.0370	0.1600	1091	10193	11284	0.038%
		BioMe	-0.0037	0.0496	0.9404	458	4703	5161	0.000%
		META-ANALYSIS	0.0308	0.0297	0.2990				



100	a 1 (T 1)
430	Supplementary Tables

- 431 1. Rank of top phecodes by site
- 432 2. Full summary statistics for PTSD PheWAS
- 433 3. PTSD PheWAS hits by PheCode category and Cross-category enrichment of PheCode categories for
- 434 PTSD PheWAS hits
- 435 4. Full summary statistics for sex-stratified PTSD PheWAS
- 436

429

437 Supplementary Figures

- 438 1. Male and female stratified PheWAS plot for PTSD Narrow
- 439 2. Male and female stratified PheWAS plot for PTSD Broad.

441 References

- 1. Sareen, J. et al. Physical and mental comorbidity, disability, and suicidal behavior associated with
- 443 posttraumatic stress disorder in a large community sample. *Psychosom. Med.* **69**, 242–248 (2007).
- 444 2. Flory, J. D. & Yehuda, R. Comorbidity between post-traumatic stress disorder and major depressive
- disorder: alternative explanations and treatment considerations. *Dialogues Clin. Neurosci.* 17, 141–
 150 (2015).
- Qassem, T., Aly-ElGabry, D., Alzarouni, A., Abdel-Aziz, K. & Arnone, D. Psychiatric Co-Morbidities
 in Post-Traumatic Stress Disorder: Detailed Findings from the Adult Psychiatric Morbidity Survey in
 the English Population. *Psychiatr. Q.* 92, 321–330 (2021).
- 450 4. Pietrzak, R. H., Goldstein, R. B., Southwick, S. M. & Grant, B. F. Physical Health Conditions
- 451 Associated with Posttraumatic Stress Disorder in U.S. Older Adults: Results from Wave 2 of the
- 452 National Epidemiologic Survey on Alcohol and Related Conditions. *J. Am. Geriatr. Soc.* 60, 296–
 453 303 (2012).
- 454 5. Pacella, M. L., Hruska, B. & Delahanty, D. L. The physical health consequences of PTSD and
 455 PTSD symptoms: a meta-analytic review. *J. Anxiety Disord.* 27, 33–46 (2013).
- 456 6. Qureshi, S. U., Pyne, J. M., Magruder, K. M., Schulz, P. E. & Kunik, M. E. The link between post-
- 457 traumatic stress disorder and physical comorbidities: a systematic review. *Psychiatr. Q.* 80, 87–97
 458 (2009).
- 459 7. Johnston, K. J. A. & Huckins, L. M. Chronic Pain and Psychiatric Conditions. *Complex Psychiatry*460 24–43 (2023) doi:10.1159/000527041.
- 461 8. Harrington, K. M. *et al.* Validation of an Electronic Medical Record-Based Algorithm for Identifying
 462 Posttraumatic Stress Disorder in U.S. Veterans. *J. Trauma. Stress* 32, 226–237 (2019).
- 463 9. Livingston, N. A. *et al.* Identifying Posttraumatic Stress Disorder and Disparity Among Transgender
- 464 Veterans Using Nationwide Veterans Health Administration Electronic Health Record Data. *LGBT*
- 465 *Health* **9**, 94–102 (2022).

- 466 10. Smoller, J. W. The use of electronic health records for psychiatric phenotyping and genomics. *Am.*
- 467 *J. Med. Genet. B Neuropsychiatr. Genet.* **177**, 601–612 (2018).
- 468 11. Stein, M. B. *et al.* Genome-wide association analyses of post-traumatic stress disorder and its
- symptom subdomains in the Million Veteran Program. *Nat. Genet.* **53**, 174–184 (2021).
- 470 12. Cai, N. et al. Minimal phenotyping yields genome-wide association signals of low specificity for
- 471 major depression. *Nat. Genet.* **52**, 437–447 (2020).
- 472 13. Duncan, L. E. *et al.* Largest GWAS of PTSD (N=20 070) yields genetic overlap with schizophrenia
- and sex differences in heritability. *Mol. Psychiatry* **23**, 666–673 (2018).
- 474 14. Olff, M. Sex and gender differences in post-traumatic stress disorder: an update. *Eur. J.*
- 475 *Psychotraumatology* **8**, 1351204 (2017).
- 476 15. Marchese, S. & Huckins, L. M. Trauma Matters: Integrating Genetic and Environmental
- 477 Components of PTSD. *Adv. Genet.* 2200017 (2022) doi:10.1002/ggn2.202200017.
- 478 16. Kim, G. S. & Uddin, M. Sex-specific and shared expression profiles of vulnerability and resilience to
 479 trauma in brain and blood. *Biol. Sex Differ.* **11**, 13 (2020).
- 480 17. Elliott, D. M., Mok, D. S. & Briere, J. Adult sexual assault: Prevalence, symptomatology, and sex
- differences in the general population. *J. Trauma. Stress* **17**, 203–211 (2004).
- 482 18. Kucharska, J. Sex differences in the appraisal of traumatic events and psychopathology. *Psychol.*483 *Trauma Theory Res. Pract. Policy* **9**, 575–582 (2017).
- 484 19. Mundy, S. S., Foss, S. L. W., Poulsen, S., Hjorthøj, C. & Carlsson, J. Sex differences in trauma
 485 exposure and symptomatology in trauma-affected refugees. *Psychiatry Res.* 293, 113445 (2020).
- 486 20. Muniz Carvalho, C. et al. Disentangling sex differences in the shared genetic architecture of
- 487 posttraumatic stress disorder, traumatic experiences, and social support with body size and
- 488 composition. *Neurobiol.* Stress **15**, 100400 (2021).
- 489 21. Kohane, I. S. *et al.* What Every Reader Should Know About Studies Using Electronic Health Record
 490 Data but May Be Afraid to Ask. *J. Med. Internet Res.* 23, e22219 (2021).

- 491 22. Wu, P. *et al.* Mapping ICD-10 and ICD-10-CM Codes to Phecodes: Workflow Development and
 492 Initial Evaluation. *JMIR Med. Inform.* 7, e14325 (2019).
- 493 23. Carroll, R. J., Bastarache, L. & Denny, J. C. R PheWAS: data analysis and plotting tools for
- 494 phenome-wide association studies in the R environment. *Bioinformatics* **30**, 2375–2376 (2014).
- 495 24. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide
- 496 association scans. *Bioinformatics* **26**, 2190–2191 (2010).
- 497 25. Nievergelt, C. M. *et al.* International meta-analysis of PTSD genome-wide association studies
 498 identifies sex- and ancestry-specific genetic risk loci. *Nat. Commun.* **10**, 4558 (2019).
- 26. Ruan, Y. *et al.* Improving polygenic prediction in ancestrally diverse populations. *Nat. Genet.* 54, 573–580 (2022).
- 501 27. Nagelkerke, N. J. D. A note on a general definition of the coefficient of determination. *Biometrika*502 78, 691–692 (1991).
- 503 28. Viechtbauer, W. Conducting Meta-Analyses in *R* with the **metafor** Package. *J. Stat. Softw.* 36,
 504 (2010).
- 505 29. Kang, B., Xu, H. & McConnell, E. S. Neurocognitive and psychiatric comorbidities of posttraumatic
 506 stress disorder among older veterans: A systematic review. *Int. J. Geriatr. Psychiatry* 34, 522–538
 507 (2019).
- 30. Facer-Irwin, E., Karatzias, T., Bird, A., Blackwood, N. & MacManus, D. PTSD and complex PTSD in
 sentenced male prisoners in the UK: prevalence, trauma antecedents, and psychiatric
- 510 comorbidities. *Psychol. Med.* **52**, 2794–2804 (2022).
- 511 31. Pietrzak, R. H., Goldstein, R. B., Southwick, S. M. & Grant, B. F. Psychiatric Comorbidity of Full and
- 512 Partial Posttraumatic Stress Disorder Among Older Adults in the United States: Results From Wave
- 513 2 of the National Epidemiologic Survey on Alcohol and Related Conditions. *Am. J. Geriatr.*
- 514 *Psychiatry* **20**, 380–390 (2012).

- 515 32. Asmundson, G. J., Coons, M. J., Taylor, S. & Katz, J. PTSD and the Experience of Pain: Research
- and Clinical Implications of Shared Vulnerability and Mutual Maintenance Models. *Can. J.*

517 *Psychiatry* **47**, 930–937 (2002).

- 518 33. Sharp, T. J. & Harvey, A. G. Chronic pain and posttraumatic stress disorder: mutual maintenance?
 519 *Clin. Psychol. Rev.* 21, 857–877 (2001).
- 34. Brennstuhl, M.-J., Tarquinio, C. & Montel, S. Chronic Pain and PTSD: Evolving Views on Their
 Comorbidity: Chronic Pain and PTSD: Evolving Views on Their Comorbidity. *Perspect. Psychiatr. Care* **51**, 295–304 (2015).
- 523 35. Giordano, N. A. et al. Differential Pain Presentations Observed across Post-Traumatic Stress
- 524 Disorder Symptom Trajectories after Combat Injury. *Pain Med.* **22**, 2638–2647 (2021).
- 525 36. Gasperi, M., Afari, N., Goldberg, J., Suri, P. & Panizzon, M. S. Pain and Trauma: The Role of
- 526 Criterion A Trauma and Stressful Life Events in the Pain and PTSD Relationship. *J. Pain* 22, 1506–
 527 1517 (2021).
- 528 37. Katrinli, S., Oliveira, N. C. S., Felger, J. C., Michopoulos, V. & Smith, A. K. The role of the immune
 529 system in posttraumatic stress disorder. *Transl. Psychiatry* **12**, 313 (2022).
- 530 38. Yehuda, R., Lehrner, A. m. y. & Rosenbaum, T. Y. PTSD and Sexual Dysfunction in Men and
- 531 Women. J. Sex. Med. **12**, 1107–1119 (2015).
- 532 39. Vézina-Gagnon, P. *et al.* Childhood sexual abuse, girls' genitourinary diseases, and psychiatric
 533 comorbidity: A matched-cohort study. *Health Psychol.* 40, 104–112 (2021).
- 40. Perkonigg, A., Owashi, T., Stein, M. B., Kirschbaum, C. & Wittchen, H.-U. Posttraumatic Stress
 Disorder and Obesity. *Am. J. Prev. Med.* 36, 1–8 (2009).
- 41. Tronieri, J. S., Wurst, C. M., Pearl, R. L. & Allison, K. C. Sex Differences in Obesity and Mental
 Health. *Curr. Psychiatry Rep.* **19**, 29 (2017).
- 538 42. Lopresti, A. L. & Drummond, P. D. Obesity and psychiatric disorders: Commonalities in
- 539 dysregulated biological pathways and their implications for treatment. *Prog.*
- 540 Neuropsychopharmacol. Biol. Psychiatry **45**, 92–99 (2013).

- 541 43. McKernan, L. C. *et al.* Posttraumatic stress disorder in interstitial cystitis/bladder pain syndrome:
- 542 Relationship to patient phenotype and clinical practice implications. *Neurourol. Urodyn.* 38, 353–
 543 362 (2019).
- 544 44. Iglesias-Rios, L., Harlow, S. D. & Reed, B. D. Depression and Posttraumatic Stress Disorder
- 545 Among Women with Vulvodynia: Evidence from the Population-Based Woman to Woman Health
- 546 Study. J. Womens Health 24, 557–562 (2015).
- 547 45. Lamvu, G., Carrillo, J., Ouyang, C. & Rapkin, A. Chronic Pelvic Pain in Women: A Review. *JAMA*548 **325**, 2381 (2021).
- 46. Meltzer-Brody, S. *et al.* Trauma and Posttraumatic Stress Disorder in Women With Chronic Pelvic
 Pain. *Obstet. Gynecol.* **109**, 902–908 (2007).
- 47. Tolin, D. F. & Foa, E. B. Sex differences in trauma and posttraumatic stress disorder: A quantitative
 review of 25 years of research. *Psychol. Bull.* **132**, 959–992 (2006).
- 48. Dueñas, H. R., Seah, C., Johnson, J. S. & Huckins, L. M. Implicit bias of encoded variables:
- frameworks for addressing structured bias in EHR–GWAS data. *Hum. Mol. Genet.* 29, R33–R41
 (2020).
- 49. Huckins, L. M. Thoughtful Phenotype Definitions Empower Participants and Power Studies.
- 557 *Complex Psychiatry* **8**, 57–62 (2022).
- 558 50. Huckins, L. M. *et al.* What next for eating disorder genetics? Replacing myths with facts to sharpen
- 559 our understanding. *Mol. Psychiatry* **27**, 3929–3938 (2022).
- 560

А

Malaise and fatique Abdominal pain Nausea and vomiting Cervicalgia Back pain Shortness of breath Nonspecific chest pain Insomnia Palo Sleep disorders Attention deficit hyperactivity disorder Other mental disorder Chronic pain Pervasive developmental disorders Alcoholism Dysthymic disorder Substance addiction and disorders Antisocia//borderline personality disorder Personality disorders Approphobia social phobia, and papir disorder Generalized anxiety disorder Armiety disorder Suicidal ideation Suicidal ideation or attempt Major depressive disorder Depression Bipolar Mond disorders Schizophrenia and other psychotic disorders Anxiety disorders Psychosis Neurological disorders Other specified nonpsychotic and/or transient mental disorders Altered mental status 500

R Narrow PTSD Broad PTSD congenital anomalies dermetologic pregnancy complications genitourinary digestive respiratory ** . circulatory system sense organs neurological mental disorders ** hematopoietic endocrine/metabolic * infectious diseases PheCode Category

Malaise and fatique Nausea and vomiting Abdominal pain Fever of unknown origin Cervicalgia Pain in joint Rash and other nonspecific skin eruption Superficial cellulitis and abscess Other symptoms/disorders or the urinary system Other dysonea Urinary tract infection Esophagitis, GERD and related diseases Courb Shortness of breath Other symptoms of respiratory system Acute upper respiratory infections Cardiac dysrhythmias Nonspecific chest pain Dizziness and olddiness (Light-headedness and vertigo) Abnormal movement Chronic pain Pain Sleep disorders Alcohol-related disorders Substance addiction and disorders Agorophobia, social phobia, and panic disorder Generalized anxiety disorder Suicidal ideation or attempt Major depressive disorder Mood disorders Neurological disorders Overweight, obesity and other hyperalimentation Disorders of fluid, electrolyte, and acid-base balance. Personality disorders Other anemias





A. Females - Narrow PTSD



injuries & poisonings Songenital anomalies musculoskeletal

dermatologic
 pregnancy complications
 genitourinary

digestive

- respiratory

circulatory system

- sense organs
- neurological
- mental disorders
- hematopoietic
- endocrine/metabolic
- neoplasms

infectious diseases

B. Males - Narrow PTSD

Personal bistopy of allerge to medicinal agents Malaise and fatigue Syncope and collapse Sweining or Servicalnia Back pain Superficial cellulitis and abscess 2FRN Diseases of esophagus Esophagitis, GERD and related diseases Other symptoms of respiratory system Shortness of breath Nonspecific chest pain Other headache syndromes Chronic pain Pervasive developmental disorders Attention deficit hyperactivity disorder Tobacco use disorder Agorophobia, social phobia, and panic disorder Dysthymic disorder Alcohol-related disorders Generalized anxiety disorder Substance addiction and disorders Anxiety disorder Anxiety disorders Suicidal ideation Depression Major depressive disorder Suicidal ideation or attempt Binolar Schizophrenia and other psychotic disorders Other specified nonpsychotic and/or transient mental disorders Neurological disorders Hypovolemia Disorders of fluid, electrolyte, and acid-base balance HIV infection, symptomatic Human immunodeficiency virus [HIV] disease Viral hepatitis C 500 750 -log10 (P-value)

A. Females - Broad PTSD





B. Males - Broad PTSD

Rersonal bistory of allergy to medicinal agents Nausea and vomiting Malaise and fatigue Acute renal failure Esophagitis, GERD and related diseases Abnormal findings examination of lungs Other dyspnea Shortness of breath Other symptoms of respiratory system Cardiac dysrhythmias Nonspecific chest pain Abnormality of gait Abnormal movement Obstructive sleep annea Toharro use disorder Alcohol-related disorders Sleep disorders Substance addiction and disorders Anxiety disorders Major depressive disorder Generalized anxiety disorder Dysthymic disorder Suicidal ideation or attempt Neurological disorders Rervasive developmental disorders Altered mental status Other anemias Disorders of fluid, electrolyte, and acid-base balance Hyptoxiamiabalance 1000 -log10 (P-value)